Selecta Biosciences, Inc nach der KE 2019
Seite 1 von 3 Neuester Beitrag: 05.01.24 16:30 | ||||
Eröffnet am: | 31.01.19 17:27 | von: centsucher | Anzahl Beiträge: | 64 |
Neuester Beitrag: | 05.01.24 16:30 | von: Vassago | Leser gesamt: | 18.999 |
Forum: | Börse | Leser heute: | 6 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | 3 > |
Selecta Biosciences, Inc. Ein kurzer Steckbrief.
Ein weiterer Finanzierungspflegefall!
Gut, jetzt ist der Kurs unten und die Finanzierung soll zu 1,5$ pro Aktie durchgeführt werden.
Aktien out vor 22,434,212 shares, danach sollen 45,471,776 shares werden.
As of November 2, 2018 , the registrant had 22,434,212 shares of common stock
We are offering 20,000,000 shares of our common stock.
We have granted the underwriters an option for a period of 30 days to purchase up to an additional 3,000,000 shares of our common stock
42,471,776 shares (or 45,471,776 shares if the underwriters exercise in full their option to purchase additional shares)
Sprich eine MK bei 1,5$ um cash!
As of December 31, 2018, Selecta Biosciences, Inc. had $37.4 million of cash and cash equivalents
We estimate that the net proceeds from this offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, will be approximately $27.9 million or $32.1 million if the underwriters exercise their option to purchase additional shares of common stock in full.
Selecta verbrennt natürlich auch ein Haufen Kohle!
We incurred net losses of $50.7 million and $45.8 million for the nine months ended September 30, 2018 and 2017
Vermutlich werden sie in 2019 weiter Kapital benötigen und auch besorgen.
Weiter haben sie noch:
The number of shares of our common stock to be outstanding immediately after this offering is based on 22,471,776 shares of our common stock outstanding as of December 31, 2018 and excludes:
•4,103,979 shares of our common stock issuable upon the exercise of stock options outstanding as of December 31, 2018 at a weighted average exercise price of $9.20 per share;
•176,432 shares of common stock issuable upon exercise of warrants outstanding as of December 31, 2018, at a weighted average exercise price of $17.32 per share;
•175,000 shares of common stock issuable upon vesting of restricted stock units outstanding as of December 31, 2018;
•1,037,031 shares of common stock reserved for issuance under our 2016 Incentive Award Plan, or the 2016 Plan, as of December 31, 2018, as well as shares that become available pursuant to provisions in our 2016 Plan that automatically increase the share reserve under the 2016 Plan; and
•539,894 shares of common stock reserved for issuance under our 2016 Employee Stock Purchase Plan, or the 2016 ESPP, as of December 31, 2018, as well as shares that become available pursuant to provisions in our 2016 ESPP that automatically increase the share reserve under the 2016 ESPP.
Steht alles in den SEC Q3 und KE
https://www.nasdaq.com/symbol/selb/sec-filings
dicker Insider-Kauf
- 2,77 Mio. Aktien zu 3,19$
- Volumen ~8,8 Mio. $
https://www.gurufocus.com/stock/SELB/insider?search=selb
https://www.globenewswire.com/news-release/2021/...siness-Update.html
Zahlen für Q3/21
- Umsatz 24 Mio. $
- Verlust 18 Mio. $
- Cash 140 Mio. $
- MK 230 Mio. $
https://ir.selectabio.com/news-releases/...ter-2021-financial-results
Zahlen für Q4/21
- Umsatz 30 Mio. $
- oper. Gewinn 4 Mio. $
- Cash 129 Mio. $
- MK 160 Mio. $
restricted cash and marketable securities which is expected to provide runway into the third quarter of 2023
https://ir.selectabio.com/news-releases/...quarter-and-full-year-2021
Dazu kommt noch die neu aufgesetzte Präsentation, welche ich denke schon auch eben für das Offering gemacht/veröffentlicht wurde. Wie wenn sie sich noch schön herrichten fürs Date danach.
38,7 Mio. $ Offering
- 27,4 Mio. neue Aktien zu je 1,41$
https://ir.selectabio.com/news-releases/...lion-underwritten-offering
https://www.sec.gov/Archives/edgar/data/1453687/...ratexpresentat.htm
https://www.benzinga.com/analyst-ratings/...-this-penny-biotech-stock
- Topline-Daten für klinische Phase-3- DISSOLVE I & II-Studien mit SEL-212 bei chronischer refraktärer Gicht bleiben für Q1 2023 auf Kurs
https://ir.selectabio.com/news-releases/...quarter-and-full-year-2022
--In patients 50 years and older, response rate with high dose SEL-212 was 65% in DISSOLVE I and 48% in DISSOLVE II
--75% of subjects in the DISSOLVE I extension phase on active treatment were responders through 12 months of therapy with no infusion reactions or new safety signals
--Favorable safety profile with 3.4% of patients with infusion reactions at high dose
Phase-3-DISSOLVE-Programm von SEL-212 bei chronisch refraktärer Gicht erreicht primären Endpunkt
https://ir.selectabio.com/news-releases/...onic-refractory-gout-meets
Zahlen für Q1/23
- Umsatz 6 Mio. $
- Verlust 22 Mio. $
- Cash 126 Mio. $
- MK 160 Mio. $
- Company to implement capital prioritization initiative, extending cash runway to 2H-2025
https://ir.selectabio.com/news-releases/...ter-2023-financial-results
Zahlen für Q2/23
- Umsatz 5 Mio. $
- Verlust 11 Mio. $
- Cash 112 Mio. $
- MK 102 Mio. $
https://ir.selectabio.com/news-releases/...ond-quarter-2023-financial